TxCell Announces Its Financial Calendar For 2015
Valbonne (France), January 30, 2015 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today its financial calendar for 2015.
February 4, 2015: Publication of full year 2014 revenues (after market)
April 1, 2015: Publication of 2014 annual results (after market)
May 6, 2015: Publication of Q1 2015 revenues (after market)
May 26, 2015: Annual shareholders’ meeting
August 4, 2015: Publication of Q2 2015 revenues (after market)
September 22, 2015: Publication of H1 2015 results (after market)
November 5, 2015: Publication of Q3 2015 revenues (after market)
In addition to these updates, investors can consult the website of the company (www.txcell.com) where information is regularly updated. All corporate and financial information on the company is available on the company’s website, in the Finance section.
About TxCell
TxCell develops innovative, cost-effective, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave(R) in refractory Crohn’s disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell has a strategic partnership for the development of Ovasave with the Swiss company Trizell Holding SA and Ferring International Center remains the intended final commercializing party. Both companies are affiliates of the Dr Frederik Paulsen Foundation. TxCell’s second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. A placebo-controlled, dose-ranging proof of principle clinical study is planned to start in the first half of 2015. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 56 employees based at its headquarters and at its manufacturing site in Besançon. For more information, please visit www.txcell.com
Help employers find you! Check out all the jobs and post your resume.
February 4, 2015: Publication of full year 2014 revenues (after market)
April 1, 2015: Publication of 2014 annual results (after market)
May 6, 2015: Publication of Q1 2015 revenues (after market)
May 26, 2015: Annual shareholders’ meeting
August 4, 2015: Publication of Q2 2015 revenues (after market)
September 22, 2015: Publication of H1 2015 results (after market)
November 5, 2015: Publication of Q3 2015 revenues (after market)
In addition to these updates, investors can consult the website of the company (www.txcell.com) where information is regularly updated. All corporate and financial information on the company is available on the company’s website, in the Finance section.
About TxCell
TxCell develops innovative, cost-effective, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave(R) in refractory Crohn’s disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell has a strategic partnership for the development of Ovasave with the Swiss company Trizell Holding SA and Ferring International Center remains the intended final commercializing party. Both companies are affiliates of the Dr Frederik Paulsen Foundation. TxCell’s second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. A placebo-controlled, dose-ranging proof of principle clinical study is planned to start in the first half of 2015. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 56 employees based at its headquarters and at its manufacturing site in Besançon. For more information, please visit www.txcell.com
Help employers find you! Check out all the jobs and post your resume.